XTuit Believes Microenvironment Approach Will Yield Cancer And Fibrosis Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Coming out of stealth with a $22 million Series A round, the biotech thinks its therapies targeting abnormal stroma could improve the activity of checkpoint inhibitors in cancer combo therapy and possibly reverse fibrosis in advanced liver disease.
You may also be interested in...
Dunsire Takes XTuit Helm As First Targets Approach The Clinic
The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.
Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
Amneal’s Generics Business Reinvigorated By New Launches
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: